Clin Transplant 21:767772 Van Schravendijk CF, Kiekens R, Pipeleers DG (1992) Pancreatic beta cell heterogeneity in glucose-induced insulin secretion
Topical and systemic drugs are indicated when patients complain about the pain and discomfort
Originally developed to treat type 2 diabetes and later approved for conditions like obesity and sleep apnea, these medications are now being touted by influencers and researchers alike for their potential as longevity drugs. Notably, a growing cohort of health professionals has been examining the potential impact of GLP-1s on longevity markers, such as cholesterol and glucose levels, which can shed light on overall health
Impaired GLP-1 secretion is considered a significant component of the pathology of overweight and obesity, metabolic syndrome and type 2 diabetes, as individuals with these conditions often exhibit reduced GLP-1 release in response to food intake compared to healthy individuals
Semaglutide has been used to help type 2 diabetics control their blood sugar, but it also appears to cause dramatic weight loss in some individuals
